A detailed history of Black Rock Inc. transactions in Ikena Oncology, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 354,842 shares of IKNA stock, worth $550,005. This represents 0.0% of its overall portfolio holdings.

Number of Shares
354,842
Previous 1,828,752 80.6%
Holding current value
$550,005
Previous $2.6 Million 77.47%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$1.24 - $1.82 $1.83 Million - $2.68 Million
-1,473,910 Reduced 80.6%
354,842 $585,000
Q1 2024

May 10, 2024

SELL
$1.27 - $2.0 $37,343 - $58,808
-29,404 Reduced 1.58%
1,828,752 $2.6 Million
Q4 2023

Feb 13, 2024

BUY
$1.33 - $4.4 $547,908 - $1.81 Million
411,961 Added 28.49%
1,858,156 $3.66 Million
Q3 2023

Nov 13, 2023

BUY
$4.09 - $6.43 $731,504 - $1.15 Million
178,852 Added 14.11%
1,446,195 $6.26 Million
Q2 2023

Aug 11, 2023

BUY
$3.5 - $7.31 $3.36 Million - $7.02 Million
960,109 Added 312.5%
1,267,343 $8.31 Million
Q1 2023

May 12, 2023

BUY
$2.62 - $4.97 $4,763 - $9,035
1,818 Added 0.6%
307,234 $1.06 Million
Q4 2022

Feb 13, 2023

SELL
$2.0 - $3.7 $393,472 - $727,923
-196,736 Reduced 39.18%
305,416 $812,000
Q3 2022

Nov 14, 2022

BUY
$3.46 - $6.0 $741,837 - $1.29 Million
214,404 Added 74.51%
502,152 $1.78 Million
Q2 2022

Aug 12, 2022

SELL
$3.23 - $7.4 $3.89 Million - $8.92 Million
-1,205,413 Reduced 80.73%
287,748 $1.28 Million
Q1 2022

May 12, 2022

BUY
$5.61 - $13.85 $725,283 - $1.79 Million
129,284 Added 9.48%
1,493,161 $9.11 Million
Q4 2021

Feb 10, 2022

BUY
$10.52 - $16.96 $9.26 Million - $14.9 Million
879,946 Added 181.83%
1,363,877 $17.1 Million
Q3 2021

Nov 09, 2021

BUY
$9.82 - $15.23 $335,775 - $520,759
34,193 Added 7.6%
483,931 $6.11 Million
Q2 2021

Aug 11, 2021

BUY
$13.27 - $26.0 $5.97 Million - $11.7 Million
449,738 New
449,738 $6.31 Million

Others Institutions Holding IKNA

About Ikena Oncology, Inc.


  • Ticker IKNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,257,500
  • Market Cap $56.2M
  • Description
  • Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...
More about IKNA
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.